<h4>Aims</h4>To compare glycaemic outcomes for two automated insulin delivery (AID) systems, the Tandem Control IQ (CIQ) and the MiniMed 780G (MM780G).<h4>Material and methods</h4>In this observational study, we evaluated 60 days of glycaemic data from 139 persons with type 1 diabetes (CIQ: 79 persons, MM780G: 60 persons), who had an active glucose sensor time ≥ 85%.<h4>Results</h4>The time with AID was median 620 (IQR, 439-755) days for CIQ users and 509 (429-744) days for MM780G users (p = 0.26). The gene discussed is INS; the disease is type 1 diabetes mellitus.